| Aug 15 |
BioLineRx GAAP EPS of $0.00, revenue of $5.39M
|
| Aug 15 |
BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
|
| Aug 14 |
biolinerx Q2 Earnings Preview
|
| Aug 8 |
BioLineRx to Report Second Quarter 2024 Results on August 15, 2024
|
| Jun 10 |
BLRX: First Quarter 2024 Results
|
| Jun 5 |
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
|
| May 30 |
BioLineRx stock jumps 14% on St. Jude clinical trial for mitoxafortide
|
| May 30 |
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)
|
| May 28 |
BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript
|
| May 28 |
biolinerx GAAP EPS of $0.00 beats by $0.29, revenue of $6.86M beats by $6.52M
|
